The Federal Antimonopoly Service (FAS) has accused Sandoz CJSC of violating the advertising law.

The service has filed charges against the Russian subsidiary of the German Sandoz (part of the Novartis Group) and its Broncho-Munal commercial on TV in 2019.

In an advertisement it was reported that the drug helps to reduce the risk of complications by three times, in particular, it can help to avoid otitis media. However, in the instructions for use of the drug, there is no mention of such properties of the drug.

According to the law, in advertising, there can be only that information about the properties and characteristics of the drug, which contains in the instructions.

The Federal Antimonopoly Service issued an order to the pharmaceutical company demanding an end to the violation of the law on advertising. The company also faces a fine of 200 to 500 thousand rubles (3 to 8 thousand USD).